Firstly, the use of a single cell line to explore the impact of kinase point mutations; future experiments should be performed in other SLC34A2-ROS1-rearranged NSCLC cell lines before extrapolating the conclusions of the drug assays to the clinical setting. This evidence concerns the gene SLC34A2 and non-small cell lung carcinoma.